STOCK TITAN
  1. Home
  2. News
  3. IPCIF

INTELLIPHARMACEUTICS INTL - $IPCIF STOCK NEWS

Welcome to our dedicated page for INTELLIPHARMACEUTICS INTL news (Ticker: $IPCIF), a resource for investors and traders seeking the latest updates and insights on INTELLIPHARMACEUTICS INTL stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INTELLIPHARMACEUTICS INTL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INTELLIPHARMACEUTICS INTL's position in the market.

News
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
Rhea-AI Summary
Intellipharmaceutics International Inc. announces its listing on NEX, a separate board of the TSX Venture Exchange, due to a Cease Trade Order. The company will be delisted from TSX and listed on NEX with a new trading symbol. Additionally, a new stock option plan has been approved.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Intellipharmaceutics Announces Cease Trade Order
Rhea-AI Summary
Intellipharmaceutics International Inc. faces a 'failure to file' cease trade order by the Ontario Securities Commission due to the Company's inability to submit required financial documents by the deadline. The order restricts trading of the Company's securities in Canada until compliance is achieved.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
Rhea-AI Summary
Intellipharmaceutics International Inc. faces delays in filing its annual audited financial statements for the fiscal year ended November 30, 2023, leading to potential issuance of a cease trade order by the Ontario Securities Commission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Intellipharmaceutics International Inc. Announces Stock Option Grant
Rhea-AI Summary
Intellipharmaceutics International Inc. issues 1,910,000 common share purchase options to certain directors, officers, and employees at a purchase price of Cdn $0.094 per Common Share. The Options will vest over a period of 2 years, expiring on February 5, 2034.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none
-
News
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
Rhea-AI Summary
Intellipharmaceutics International Inc. (IPCIF, IPCI) has received conditional approval to list its common shares on the TSX Venture Exchange as a Tier 2 Life Science Issuer. The final approval is pending the company satisfying certain conditions required by the TSXV. The company expects a seamless transition from trading on the TSX to the TSXV, with the shares continuing to trade under the symbols 'IPCI' and 'IPCIF' on the TSXV and OTCQB Marketplace, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none
-
News
Intellipharmaceutics Announces Third Quarter 2023 Results
Rhea-AI Summary
Intellipharmaceutics International Inc. reports Q3 2023 results and provides updates on corporate developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Intellipharmaceutics Reports Director Election Results
Rhea-AI Summary
Intellipharmaceutics reports that the five incumbent directors were elected at the annual meeting of shareholders. All other resolutions were also approved.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Intellipharmaceutics Announces Second Quarter 2023 Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Intellipharmaceutics Announces Third Quarter 2022 Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock IPCIF logo
INTELLIPHARMACEUTICS INTL

OTC:IPCIF

IPCIF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

IPCIF Stock Data

1.99M
32.51M
1.76%
3.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Etobicoke

About IPCIF

since 1998, intellipharmaceutics has been an innovator in the international pharmaceutical market. the company’s patented hypermatrix™ technology is a unique and validated multidimensional controlled-release drug delivery platform that can be applied to the development of a wide range of existing and new pharmaceuticals. based on this technology, intellipharmaceutics is developing a pipeline of both generic and new drugs across a range of therapeutic classes. intellipharmaceutics international was listed on the nasdaq and tsx on october 22, 2009 (nasdaq: ipci; tsx: i).